OSE Immunotherapeutics to Present at 5th Annual Immuno-Oncology: BD&L and Investment Forum

NEXT STORY
Immunicum AB (publ) Announces Outcome of Subscription in Employee Incentive Program 2019/2022
PREV STORY
IBA signs contract to install proton therapy center in Italy
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Zealand Pharma to present new clinical Phase 2 results on glepaglutide for the treatment of short bowel syndrome at the DDW conference in the U.S.

Press Release - No. 14/2018 Zealand Pharma to present new clinical Phase 2 results ...

author_avatar
NASDAQ Market News

Rexahn Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Update on RX-3117 Development

author_avatar
NASDAQ Market News

Ontario Home Respiratory Services Association Calling on Government to Change Planned Cuts to Funding for Respiratory Devices During Pandemic

author_avatar
NASDAQ Market News